Market Place
Sourcing Support
Astellas Pharma`s Veozah Receives Approval in Canada
03 Dec 2024 //
HEALTH CANADA
Astellas To Present VEOZA Data At IMS World Menopause Congress
10 Oct 2024 //
PR NEWSWIRE
Astellas to Present VEOZAH™ Data at 2024 Menopause Society Annual Meeting
04 Sep 2024 //
PR NEWSWIRE
Astellas Initiates Phase 3 Study Of Fezolinetant For VMS In Breast Cancer
27 Aug 2024 //
PR NEWSWIRE
Bayer posts pivotal data on rival to Astellas in menopause space
18 May 2024 //
FIERCE PHARMA
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS
03 Mar 2024 //
PR NEWSWIRE
Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl
01 Feb 2024 //
PR NEWSWIRE
Astellas` VEOZA Approved by EC for Treatment of Vasomotor Symptoms
10 Dec 2023 //
PR NEWSWIRE
Astellas` Veozah among new drugs recommended for authorization by EMA
13 Oct 2023 //
ENDPTS
Astellas Highlights VEOZAH Data at 2023 Annual Meeting of The Menopause Society
18 Sep 2023 //
PR NEWSWIRE
Astellas shares +VE results from ph3b trial Fezolinetant for menopause symptoms
28 Jun 2023 //
PHARMAFILE
Astellas` VEOZAH™ Approved by U.S. FDA for Vasomotor Symptoms Due to Menopause
13 May 2023 //
PR NEWSWIRE
FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes
12 May 2023 //
PR NEWSWIRE
Results from Astellas` Pivotal Phase 3 SKYLIGHT 1 Study of Fezolinetant
13 Mar 2023 //
PR NEWSWIRE
Astellas has menopause accelerated approval ambition thwarted by FDA
21 Feb 2023 //
FIERCE BIOTECH
Astellas Provides Update on Fezolinetant New Drug Application in U.S.
19 Feb 2023 //
PR NEWSWIRE
Astellas to Present Findings from Phase 3 Study of Fezolinetant in Oral Session
12 Oct 2022 //
PRNEWSWIRE
EMA Accepts Astellas` Marketing Authorization Application for Fezolinetant
01 Oct 2022 //
PRNEWSWIRE
Astellas Announces Topline Results from PIII Study of Fezolinetant in China
04 Sep 2022 //
PRNEWSWIRE
Astellas` menopause therapy accepted for FDA review
19 Aug 2022 //
FIERCEBIOTECH
U.S. FDA Accepts Astellas` New Drug Application for Fezolinetant
17 Aug 2022 //
PRNEWSWIRE
Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant
14 Mar 2022 //
PRNEWSWIRE
Astellas Shows Topline Results From Long-Term Phase 3 Safety, pitches to FDA/EMA
08 Mar 2022 //
PHARMALIVE
Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2 Trial
24 Sep 2021 //
PRNEWSWIRE
Astellas to Present Fezolinetant Data at North American Menopause Society 2021
22 Sep 2021 //
PRNEWSWIRE
Astellas scores a pair of trial wins for menopausal hot flash med, raising pitch
20 Feb 2021 //
ENDPTS
Astellas Announces Positive Topline Results from Two Phase 3 Pivotal
19 Feb 2021 //
PRNEWSWIRE
Astellas’ fezolinetant reduced severity of VMS in women in Phase III trial
19 Feb 2021 //
CLINICALTRIALSARENA
Astellas Initiates Ph3 Clinical Trials for Fezolinetant
06 Aug 2019 //
PR NEWSWIRE
Astellas Appoints SVP and Head Clinical and Research QA
06 Aug 2019 //
CONTRACT PHARMA
